Cancers 2013, 5(2), 550-568; doi:10.3390/cancers5020550
Review

99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies

 and *
Received: 22 March 2013; in revised form: 13 April 2013 / Accepted: 10 May 2013 / Published: 15 May 2013
(This article belongs to the Special Issue Cancer Cell Imaging)
View Full-Text   |   Download PDF [383 KB, uploaded 15 May 2013]
Abstract: Evaluation of efficacy of anti-cancer therapy is currently performed by anatomical imaging (e.g., MRI, CT). Structural changes, if present, become apparent 1–2 months after start of therapy. Cancer patients thus bear the risk to receive an ineffective treatment, whilst clinical trials take a long time to prove therapy response. Both patient and pharmaceutical industry could therefore profit from an early assessment of efficacy of therapy. Diagnostic methods providing information on a functional level, rather than a structural, could present the solution. Recent technological advances in molecular imaging enable in vivo imaging of biological processes. Since most anti-cancer therapies combat tumors by inducing apoptosis, imaging of apoptosis could offer an early assessment of efficacy of therapy. This review focuses on principles of and clinical experience with molecular imaging of apoptosis using Annexin A5, a widely accepted marker for apoptosis detection in vitro and in vivo in animal models. 99mTc-HYNIC-Annexin A5 in combination with SPECT has been probed in clinical studies to assess efficacy of chemo- and radiotherapy within 1–4 days after start of therapy. Annexin A5-based functional imaging of apoptosis shows promise to offer a personalized medicine approach, now primarily used in genome-based medicine, applicable to all cancer patients.
Keywords: 99mTc-HYNIC-Annexin A5; annexine a5; molecular imaging; SPECT; cancer; efficacy of therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Schaper, F.L.; Reutelingsperger, C.P. 99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies. Cancers 2013, 5, 550-568.

AMA Style

Schaper FL, Reutelingsperger CP. 99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies. Cancers. 2013; 5(2):550-568.

Chicago/Turabian Style

Schaper, Frédéric L.; Reutelingsperger, Chris P. 2013. "99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies." Cancers 5, no. 2: 550-568.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert